Clinical and economic assessment of feasibility of using quadritherapy in patients with reduced ejection fraction chronic heart failure in medical organizations of the Moscow Region
Objective: assessment of feasibility of using four-component drug therapy for patients with chronic heart failure with reduced ejection fraction (CHFrEF) in medical organizations of the Moscow Region (MR).Material and methods. Clinical and economic analysis of combined standard therapy with angioten...
Saved in:
| Main Authors: | A. D. Ermolaeva, T. N. Ermolaeva, K. A. Kokushkin |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2023-11-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/889 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Сost-effectiveness of preventing cardiovascular death and achieving the target indicator "Reduction of the cardiovascular mortality of the population" of the State Program "Health Development" when using valsartan+sacubitril, dapagliflozin and empagliflozin in patients with heart failure with reduced ejection fraction
by: M. V. Zhuravleva, et al.
Published: (2023-04-01) -
Cost-effectiveness of dapagliflozin as part of various treatment regimens for prevention of cardiovascular death and achieving the target indicator "Reduction of cardiovascular mortality" of the State Program "HealthCare Development" in patients with heart failure with reduced ejection fraction
by: M. V. Zhuravleva, et al.
Published: (2024-08-01) -
Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure
by: M. V. Zhuravleva, et al.
Published: (2022-01-01) -
Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01) -
Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases
by: M. V. Zhuravleva, et al.
Published: (2020-11-01)